Peregrine's Bavituximab HCV Abstract Accepted for Presentation at the 46th Annual Meeting of EASL

Peregrine to Report Third Quarter Fiscal Year 2011 Financial Results After Market Close on March 11, 2011

Peregrine Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting

Peregrine Completes Patient Enrollment in Phase Ib HCV/HIV Coinfection Trial

Peregrine Announces Initiation of Investigator-Sponsored Trial in HER2-Negative Metastatic Breast Cancer

Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C

Peregrine Initiates Randomized Phase II Trial of Bavituximab in Pancreatic Cancer

Peregrine Completes Treatment of Last Patient in Phase II Cotara(R) Brain Cancer Trial

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2011 Financial Results and Recent Developments

Avid Bioservices Secures New Biosimilar Development Project